Alignment Healthcare (ALHC) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.25
- Estimate
- $0.20
- Surprise
- +24.4%
- Revenue (period 2026-06-30)
- $1.34B
- Score today
- 5.8/10
Revenue source: xbrl.
How the report landed
Alignment Healthcare (ALHC) beat the $0.20 estimate with adjusted EPS of $0.25 — a large 24.4% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALHC Sell at 5.8/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +24.4% surprise compares with a +41.8% four-quarter average. Next scheduled report: 2027-02-25.
What argues against it
- Concentration risk — Customer: CMS contracts
- Quality below floor (3.9 < 4.0)
- Momentum score 2.2/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.04
- Price target
- $9.39
- Stop
- $6.55
- Upside to target
- +33.4%
- Reward-to-risk
- 2.3:1
The stock trades at 50.0× trailing but 12.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 27 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.
ALHC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Healthcare Plans
- Market cap
- $1.46B
- P/E (fwd)
- 12.6
- P/E (ttm)
- 50.0
- 52-week range
- $6.01–$25.12
- Off 52-week high
- 72.0%
- RSI (14)
- 27
- Volume vs avg
- 0.05×
- Score today
- 5.8/10